GUM TECH INTERNATIONAL INC - Zicam Cold Remedy To Be Subject Of Upcoming Scientific - Presentation
New York, New York, Mar 14, 2002 (Market News Publishing via COMTEX) -- Gum Tech International Inc., developer and distributor of Zicam(r) Cold Remedy and Zicam(r) Allergy Relief, announced to-day that the cold remedy will be the subject of an upcoming scientific presentation by Sherif Beniameen Mossad, M.D., F.A.C.P., F.I.D.S.A. at the 10th International Congress of Infectious Diseases (ICID) taking place in Singapore this week.
During a poster session at the conference, Dr. Mossad, of the Department of Infectious Diseases at the Cleveland Clinic Foundation, will present the results of a new clinical study designed to specifically measure the effects of a zincum gluconicum nasal gel (Zicam Cold Remedy) on patients identified as having rhinovirus. The study results are currently undergoing peer review as a preliminary to possible publication in a professional journal.
The study was funded by Gum Tech International, Inc.
About Gum Tech International, Inc.
Gum Tech International, Inc., based in Phoenix, Arizona, is an innovative nutrient and drug delivery technology company engaged in the development, manufacture and marketing of delivery systems for bioactive compounds. Gum Tech produces, markets and sells Zicam(r) Cold Remedy nasal gel, a patented, revolutionary homeopathic remedy that has been clinically proven to significantly reduce the duration and severity of the common cold. In a study published in the October 2000 issue of ENT - Ear, Nose and Throat Journal, the Zicam(r) Cold Remedy product was shown to reduce the duration of the common cold by an average of 75 percent when taken at the onset of symptoms. The company also manufactures and markets Zicam(r) Allergy Relief nasal gel, a homeopathic remedy designed to provide relief to allergy sufferers. For additional information, please contact William Hemelt, Chief Financial Officer, at 602.387.5134 or whemelt@gum-tech.com. Gum Tech is located at 2375 East Camelback Road, Phoenix, Arizona 85016. Gum Tech Forward Looking Statement Disclaimer: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the possible publication of Dr. Mossad's clinical study in a professional journal. These forward-looking statements are based on the Company's expectations and are subject to risks and uncertainties, many of which cannot be predicted or quantified and are beyond the Company's control. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. Factors that could cause actual results to differ materially from the Company's expectations are described in the Company's reports filed pursuant to the Securities Exchange Act of 1934.
CONTACT: TEL: 602.387.5134 William Hemelt, Gum Tech International
E-MAIL: whemelt@gum-tech.com
TEL: 602.870.4752 Susan M. Bryan, Christensen & Associates
E-MAIL: sbryan@cabestpractice.com |
